Journal of Biomaterials Applications最新文献

In the repair of large bone defects, loss of the periosteum can result in diminished osteoinductive activity, nonunion, and incomplete regeneration of the bone structure, ultimately compromising the efficiency of bone regeneration. Therefore, the research and development of tissue-engineered periosteum which can replace the periosteum function has become the focus of current research. The functionalized electrospinning periosteum is expected to mimic the natural periosteum and enhance bone repair processes more effectively. This review explores the construction strategies for functionalized electrospun periosteum from the following perspectives: ⅰ) bioactive factor modification (bone morphogenetic protein-2 (BMP-2), vascular endothelial growth factor (VEGF) etc.), ⅱ) inorganic compound modification, ⅲ) drug modification, ⅳ) artificial periosteum in response to physical stimuli. Furthermore, the construction of artificial periosteum through electrospinning, in conjunction with other strategies, is also analyzed. Finally, the current challenges and prospects for the development of electrospinning periosteum are also discussed.

This study investigated the efficacy and safety of magnesium alloy screws in repairing small bone fractures using goat lateral femoral condyle fracture models. The animals were randomized into an experimental group receiving magnesium alloy screws (CS/Ф 3.2 × 28 mm, Suzhou Zhuoqia Medical Technology) and a control group receiving titanium alloy screws (CS/Ф 3.2 × 28 mm, Samo Medical Technology Co., Ltd). Postoperative evaluations at 3- and 6-month intervals included assessments of fracture repair, animal health, hematological parameters, histology, and screw degradation. Hematological tests revealed no significant intergroup variations. While gas accumulation near the magnesium screws was noted, the fracture healing outcomes were similar between the magnesium and titanium screw groups, with no deleterious health effects attributed to magnesium screw degradation. Gas liberation during magnesium degradation had no detrimental effect on small fracture recovery. Magnesium screw implementation appears to present no general health risks. Consequently, magnesium alloy could be a promising biomaterial for future fixation screw applications in orthopedics.

Trophoblast dysfunction during pregnancy time is majorly involved to lead pathogenesis of preeclampsia. In the present investigation, the facile nanoformulation by Zein protein particles functionalized with hydroxypropyl-beta-cyclodextrin (β-CD) and co-encapsulated with curcumin and eugenol compounds (Cu/Eu@H-β-CD-ZNPs) is developed to achieve enhanced therapeutic potential in the treatment of preeclampsia. To investigate the positive trophoblast function, trophoblast cells were treated and observed for in vitro cell proliferation, invasion and migration ability under hypoxic condition. The Cu/Eu@H-β-CD-ZNPs have significantly induced the restoration ability of trophoblast cells. In vivo animal study was performed using pregnancy rat models by inducing LPS and observed the hypertension-related factors. The Cu/Eu@H-β-CD-ZNPs prominently down-regulated the expressions of serum and placental pro-inflammatory factors (IL-6, TNF-α, IL1β, and IFN-γ). Additionally, p65 and TLR4 protein expressions in LPS-induced model were effectively downregulated after administration of Cu/Eu@H-β-CD-ZNPs. Results of current investigation provides evidence for combination of Cur/Eug with novel H-β-CD-ZNPs formulation have therapeutic potential on the treatment of pregnancy-induced hypertension by rat models.

Cartilage deterioration in patients with osteoarthritis presents a significant challenge, primarily attributable to the inadequate oral bioavailability and poor dosage compliance of chondroprotective agents. The Chondroitin Sulphate (CS) is a stabilizing and reducing agent for metal NP as well as homing agent by binding to surface molecules (CD44, L-selectin, P-selectin, and annexin-6) of chondrocytes at the OA site. This study was designed to develop intra-articular magnetic gold nanohybrids for the co-delivery of chondroitin sulfate, glucosamine sulfate, and gold, aiming to achieve synergistic anti-inflammatory and cartilage regenerative effects and in vitro assessments of drug release were conducted. Additionally, in animal study, the male albino rats underwent anesthesia by inhaling isoflurane using the open-drop exposure method, and chondrocytes were then harvested for cytotoxicity and biocompatibility assays. Physical characterization revealed 66 nm particle size with uniform distribution and colloidal stability of MGN-CS-GS. Zeta potential and FTIR analysis showed electrostatic interaction between the carboxyl and amino groups of MGN-CS and GS. VSM and EDX confirmed paramagnetic and core-shell characteristics of nanohybrids, respectively. It was found that the MGN-CS-GS released more CS (72%) and GS (85%) at acidic pH with continuous release pattern, which will improve patient compliance. The nanohybrid's cytotoxicity assay demonstrated excellent biocompatibility and cellular viability of OA chondrocytes triggered by interleukin-1β (IL-1β) compared to marketed formulation. The results demonstrated that MGN-CS-GS continuously released both drugs with high biocompatibility and cellular viability of OA chondrocytes. The successful synthesis of MGN-CS-GS is a foundation for further research on its potential application as a novel co-drug carrier nanohybrid system.

Drospirenone (DROP) is a highly effective, low-toxicity, safe new generation progestin that counteracts estrogen-related sodium retention, is well tolerated, and has a positive effect on premenstrual syndrome (PMS). However, the low water solubility of DROP and its chemical instability resulted in low bioavailability. In this study, we developed a two-step delivery system to enhance drospirenone's solubility and stability. We prepared a drospirenone liposome complex to optimize the encapsulation process and achieve an encapsulation efficiency of (84.9 ± 0.73) %, with an 878-fold increase in solubility under optimal conditions. To address the instability of high drug-loading liposomes, we immobilized the drospirenone liposome inclusion complex using a cellulose-based hydrogel. The system achieved uniform loading of liposomes in the hydrogel, as confirmed by SEM and FTIR analysis. 0.5 g hydrogel can be loaded with up to 96.48 mg drospirenone, and the encapsulation efficiency is (80.4 ± 1.17%). It was indicating the potential for wider application of drospirenone with enhanced water solubility and improved stability. At the same time, it also provides support for sustained-release systems or large dose drug delivery.

HA/Fe composites were prepared by powder metallurgy. The effects of ball milling time, pressing pressure, and sintering temperature on the porosity and hardness of the composites were investigated, and their mechanical properties and biocompatibility were evaluated. The results show that as the ball milling time increases (30∼60min), the average particle size initially decreases and then increases (82.91∼53.49∼77.98 μm). Additionally, an appropriate increase in pressing pressure and sintering temperature can decrease the composite's porosity and increase its hardness. When the pressing pressure is 27 KN and the sintering temperature is 1000°C, the composite material has excellent mechanical properties (hardness 268.5 Hv, compressive strength 106.736 MPa) and good in vitro biocompatibility. The hemolysis rate of the sample was 1.719518 %. When the concentration of the extract was 50 %, the cell proliferation rate could reach 136.26 %. Furthermore, the degradation properties of the composites were studied. At 12 months the corrosion rate of HA/Fe composites reached 0.3173 mm/a. It was also observed varying degradation mechanisms was different in different soaking cycles, and the dominant degradation mechanism was gradually changed from HA in the early stage to Fe in the later stage, which played a positive guiding role in the development of iron matrix composites with different degradation rates.

Although KI24RGDS peptide hydrogel that acts as a cell adhesion has been reported to repair tissue in meniscus injury, its effect on tendon injuries remains unknown. The purpose of this study was to clarify the effect of KI24RGDS for tendon repair based on histological and biomechanical evaluation. After introducing defects (length: 10 mm; width: 3 mm) at the centers of rabbits' patellar tendons, and the KI24RGDS group was implanted with KI24RGDS and observed for 8 weeks. KI24RGDS implantation resulted in limited tendon elongation and better histological scores with uniformed collagen fiber orientation and early vascularization. The failure load of the patellar tendon was higher in the KI24RGDS group than that in the defect group (p < 0.05) and no significant difference with the control group (intact patellar tendon) at 8 weeks postoperatively. In conclusion, KI24RGDS administration might have therapeutic potential for tendon injuries by accelerating collagen remodeling.

In this work, we are comparing biomimetic niosomal nanoparticles (BNNs) with biomimetic liposomal nanoparticles (BLNs) and studying their drug carrier properties. A-BNNs and A-BLNs are prepared by lipid hydration method and characterized using DLS for size and zeta potential analysis, surface morphology by SEM, structural details by TEM, crystallinity and phase change by XRD, thermodynamic properties by DSC, TGA and DTGA, drug carrier properties by entrapment efficiency, drug release studies by open-end tube method and its mechanistic assessment by fitting with various models such as zero order, first order, Higuchi and Korsmeyer-Peppas models. The A-BNNs had an average size of 157.0 ± 3.58 nm and A-BLNs had an average size of 173 ± 1.24 nm. The A-BNNs had an average zeta potential of -29.0 ± 1.11 mV and A-BLNs had an average zeta potential of -46.5 ± 1.11 mV. The A-BNNs have an average entrapment efficiency of 94 ± 0.4% and A-BLNs have an average entrapment efficiency of 98 ± 0.14%. The BNNs have an average drug release of 78.12 ± 1.57% and A-BLNs have an average release of 98.41 ± 1.87% over 24 hours. Our results show that the vesicular size dependence influences the resulting nanoparticle drug carrier properties. This is a robust demonstration of the phenomena at the nanoscale that the precursor vesicular system size dependency will be reflected in bulk-engineered nanoparticle properties. These novel nanoparticles are potential candidates for development as an injection to suppress clots in stroke and myocardial infarction.

Silicone contact lenses (SCL), as an emerging ocular drug delivery system, achieve controlled drug release. However, the existing drug loading methods have limitations such as low drug uptake, complicated operation process, poor welling rate and transmittance of the lens after drug loading. In this study, an effective microemulsion soaking method was proposed to increase the drug-loading capacity of silicone contact lenses. Levofloxacin (LVF) was encapsulated into the microemulsion by direct agitation, then the microemulsion was loaded into silicone contact lenses using the immersion method. The adsorption capacity of levofloxacin and its effect on drug release kinetics were explored. The results showed that the particle size of the microemulsion was approximately 160 nm. The levofloxacin microemulsion soaking method (LVF-ME-SCL) significantly enhanced the drug loading of levofloxacin in the silicone contact lenses, achieving a maximum drug loading of 216.32 ± 1.15 μg/lens (p > 0.05). The total release rate of levofloxacin was 95.96% when the sustained release time was 10 h, and the drug leakage observed after 10 h was negligible. The survival rate of E. coli and S. aureus in LVF-ME-SCL-1 (LVF concentration was 4.8 mg/mL) group was 0 and 19.33 ± 0.02% (p < 0.0001), with a significant difference, indicating that the drug-loaded silicone contact lenses exhibited effective bactericidal properties against E. coli and S. aureus. Following the addition of maximum levofloxacin, the surface contact angle of silicone contact lenses decreased significantly to 32.88 ± 1.19° (p > 0.05), while the swelling, mechanical properties, and oxygen permeability remained relatively unchanged. There was no significant decrease in the transmittance of the contact lenses after the addition of levofloxacin, which remained above 95%. In conclusion, these results show that the microemulsion impregnation method effectively improves the drug loading and sustained release time of levofloxacin, and maintains lens performance stability before and after drug loading, so it is expected to be used in ophthalmic treatment.

Building on our innovative approach to combatting cancer, this study explores the development of a sophisticated hybrid nanocarrier system leveraging the unique properties of allyl oxide cucurbit[6]uril with galactose clusters (AOQ[6]@Gal) to modify ZIF-8 nanoparticles. These nanoparticles are designed to encapsulate and efficiently deliver the anticancer drugs doxorubicin (DOX) and curcumin (CUR), enhancing their water solubility and stability, while also providing active targeting towards hepatocellular carcinoma cells. The comprehensive characterization of AOQ[6]@Gal@ZIF-8@Drug nanoparticles revealed promising outcomes, including drug loading efficiencies of 9.7% for DOX and 8.3% for CUR, alongside a pH-responsive release profile that ensures effective drug delivery in the tumor microenvironment. Cytotoxicity studies underscored the hybrid system's superior safety profile, exhibiting minimal toxicity towards normal hepatocytes HL7702 and pronounced cytotoxic effects against hepatocellular carcinoma cells HepG2. These results highlight the hybrid nanocarrier's potential as a targeted, efficient, and safe platform for the delivery of chemotherapy agents in the treatment of liver cancer.